

Biointelligence on a Dish: Lab-Grown Brains for Human-Centric Drug Development

Dr. Nisim Perets, CEO and Co-founder

Company name: Itay&Beyond

Website: Itayandbeyond.com

CEO name: Dr. Nisim Perets

CATEGORY: Biotech/Pharma

SESSIONS:

- Rewiring the Brain; Breakthroughs in Neurotech and Neuromodulation
- Frontiers in Biochip and Bio-Devices; Advancing Technological Systems with Cutting-Edge Biology

Answers below should not exceed 60 words per question:

Executive Summary:

Itay&Beyond is a neurotech company leveraging brain-on-a-chip technology for CNS drug discovery. Following successful proof-of-concept studies using patient-derived organoids from ASD and epilepsy, the platform targets a multibillion-dollar market. The company's business model focuses on building a pipeline of novel, effective compounds for out-licensing to pharma via joint development agreements (JDAs), backed by a strong team and early traction.

Core Technology What is the technology, its uniqueness, and its value proposition?

From a urine sample to patient-derived lab-grown brain tissue-on-a-chip, **Itay&Beyond** integrates organoids with electronics to simulate neural activity. This unique platform provides functional efficacy readouts, enabling early screening of novel and repurposed CNS compounds. It increases success rates, reduces clinical trial risk, and offers a powerful tool for precision drug development.

Product Profile/Pipeline Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships.

Itay&Beyond's brain-on-a-chip technology has completed a successful proof of concept (POC), including the submission of a significant scientific paper that describes some of the results. We are conducting a funded proof-of-concept (POC) study with a pharmaceutical company and collaborating with Hadassah and Schneider hospitals. Our first proprietary compound, validated in the technology, is at the hit-to-lead process.

Business Strategy Briefly describe how the company will apply its core technology, generate short-term and long-term revenues

Itay&Beyond is conducting several funded short-term pilot studies with small-medium pharma partners, both as external validation and for revenue. The core business strategy focuses on building a proprietary drug pipeline for out-licensing and joint development agreements (JDAs), expected to generate long-term revenue within 1–2 years.

What's Next? R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans

Itay&Beyond aims to clinically validate its brain-on-chip platform by comparing drug efficacy with physician-prescribed treatments. The company plans to expand its neuroscience and AI teams, deepen ties with Medical Centers, and secure additional funding to advance R&D, scale operations, and accelerate commercialization of its neuropsychiatric innovations.